Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 13-valent pneumococcal conjugate vaccine (PCV13) in children 6–17 years in India
2019-000890-21Phase 4
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 13 in Pneumococcal pneumonia (PP) and pneumococcal disease, sponsored by Pfizer. Primary endpoint: Local reactions within 7 days after vaccination.
02
Drugs
Prevnar 13
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal disease
Beyond the preview
Go deeper on 2019-000890-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000890-21.